IQ-AI Limited

Equities

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Delayed London S.E. Other stock markets 06:38:10 2024-06-03 am EDT			5-day change	1st Jan Change
1.598 ^GBX	+10.18%		+14.11%	-66.01%

May. 23	Celadon ships to US; Oxford BioDynamics-Goodbody pact	AN
May. 20	IQ-AI subsidiary gets second FDA rare paediatric disease designation	AN

IQ-AI Ltd Provides Sales Guidance for 2019

April 30, 2019 at 07:00 am EDT

IQ-AI Ltd. provided sales guidance for 2019. The company's objectives for 2019 are to expand sales and continue to develop new products which utilise areas of expertise where company believe company have scientific and technological leadership. As a result of product development and new users, sales have continued to accelerate in 2019. The company expects sales for the full year 2019 to more than double those for 2018.

Latest news about IQ-AI Limited

Celadon ships to US; Oxford BioDynamics-Goodbody pact	May. 23	AN
IQ-AI subsidiary gets second FDA rare paediatric disease designation	May. 20	AN
IQ-AI's Imaging Biometrics Gets Second Rare Disease Designation for Drug Candidate	May. 20	MT
Ingenta trades in line; Triple Point Social NAV up	May. 17	AN
IQ-AI Unit Delivers Software to Insel Gruppe	May. 17	MT
IQ-AI subsidiary gets rare paediatric disease designation FDA	May. 10	AN
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	May. 10	MT
EARNINGS AND TRADING: Trident Royalties swings to profit	May. 02	AN
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	Apr. 29	CI
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing	Feb. 26	MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	Feb. 22	MT
IQ-AI shares sink on discounted placing fundraise	Feb. 22	AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	Feb. 09	MT
IQ-AI subsidiary asked by FDA to resubmit and modify application	Feb. 09	AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	Feb. 02	MT
IQ-AI celebrates USD100,000 grant for subsidiary	Feb. 02	AN
IQ-AI falls after subsidiary notes launch of treatment access scheme	Jan. 10	AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	Jan. 10	MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	Dec. 19	MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	Dec. 19	AN
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment	Dec. 05	MT
IQ-AI stock rises on positive interim results from glioblastoma trial	Dec. 05	AN
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment	Nov. 08	MT
IQ-AI says Imaging Biometrics submits paediatric rare disease request	Nov. 08	AN

Chart IQ-AI Limited

Duration

Period

More charts

Company Profile

IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.

Sector

Healthcare Facilities & Services

Calendar

2024-09-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
IQ-AI LIMITED	-66.01%	4.09M
SONIC HEALTHCARE LIMITED	-24.66%	7.76B
RADNET, INC.	+68.65%	4.33B
SYNLAB AG	-3.15%	2.64B
DR. LAL PATHLABS LIMITED	+3.74%	2.63B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-46.17%	2.16B
NEOGENOMICS, INC.	-15.27%	1.75B
FLEURY S.A.	-22.12%	1.46B
METROPOLIS HEALTHCARE LIMITED	+13.62%	1.17B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.81%	1.14B

Medical & Diagnostic Laboratories